Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levothyroxine in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism
NCT03096613Phase 4Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levothyroxine sodium in heart failure (HF) and hypothyroidism (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Six-minute Walk Test Distance at 24 weeks. Status: unknown.
02
Drugs
levothyroxine sodium
03
Conditions
heart failure (HF)hypothyroidism
Beyond the preview
Go deeper on NCT03096613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096613.